Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Cosimo Sperti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7869-8715; OpenAlex author ID A5003280879, A5084347720. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 11 papers · 2022: none · 2023: 6 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 41

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  4. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  5. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  6. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  7. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  8. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  9. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  10. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  11. Paraneoplastic myopathy-related rhabdomyolysis and pancreatic cancer: A case report and review of the literature. Last author DOI 10.12998/wjcc.v11.i28.6823↗
  12. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  13. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic liter… Co-author DOI 10.1007/s12149-021-01629-0↗
  14. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  15. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  16. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  17. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  18. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  19. Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study. Co-author DOI 10.3390/biomedicines9070845↗
  20. Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer. First author DOI 10.3390/cancers13061277↗
  21. Does Pancreatic Fistula Affect Long-Term Survival after Resection for Pancreatic Cancer? A Systematic Review and Meta-Analysis. Last author DOI 10.3390/cancers13225803↗
  22. The Prognostic Value of Low Muscle Mass in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis. Last author DOI 10.3390/jcm10143033↗
  23. Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm9072169↗
  24. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  25. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  26. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  27. Surgery for Recurrent Pancreatic Cancer: Is It Effective? Last author DOI 10.3390/cancers11070991↗
  28. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  29. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phas… Co-author DOI 10.1016/j.phrs.2018.03.013↗
  30. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  31. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer. Co-author DOI 10.3748/wjg.v23.i24.4399↗
  32. Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mell… Co-author DOI 10.1016/j.cca.2016.02.018↗
  33. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  34. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  35. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  36. Mesenteric-Portal Vein Resection during Pancreatectomy for Pancreatic Cancer. Last author DOI 10.1155/2015/659730↗
  37. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? Co-author DOI 10.4251/wjgo.v7.i12.375↗
  38. Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318273096c↗
  39. Accuracy of CA 19-9 and radiologic imaging in detecting recurrence after resection for pancreatic cancer. Co-author DOI 10.6092/1590-8577/1886↗
  40. Fatal pneumococcal sepsis eleven years after distal pancreatectomy with splenectomy for pancreatic cancer. Last author DOI 10.6092/1590-8577/1074↗
  41. The effect of age on long-term survival after pancreatic resection for pancreatic cancer Last author DOI 10.1186/1471-2318-11-s1-a4↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lucia Moletta · 9 shared papers, 2015–2023 · strength 1.16
  2. Simone Serafini · 7 shared papers, 2019–2023 · strength 1.01
  3. Elisa Sefora Pierobon · 3 shared papers, 2019–2023 · strength 0.46
  4. Stefano Merigliano · 3 shared papers, 2015–2021 · strength 0.27
  5. Andrea Grego · 2 shared papers, 2020–2021 · strength 0.27
  6. Sergio Pedrazzoli · 6 shared papers, 2011–2017 · strength 0.26
  7. Valentina Beltrame · 5 shared papers, 2011–2017 · strength 0.26
  8. Daniela Basso · 3 shared papers, 2013–2021 · strength 0.23
  9. Mario Plebani · 3 shared papers, 2013–2021 · strength 0.23
  10. Andrea Costantini · 1 shared paper, 2023 · strength 0.22
  11. Federico Canzian · 3 shared papers, 2016–2019 · strength 0.15
  12. Thilo Hackert · 3 shared papers, 2016–2019 · strength 0.15
  13. Renata Talar‐Wojnarowska · 3 shared papers, 2016–2019 · strength 0.15
  14. Gabriele Capurso · 3 shared papers, 2016–2019 · strength 0.15
  15. Daniele Campa · 3 shared papers, 2016–2019 · strength 0.15
  16. Oliver Strobel · 3 shared papers, 2016–2019 · strength 0.15
  17. Francesca Tavano · 3 shared papers, 2016–2019 · strength 0.15
  18. Pavel Souček · 3 shared papers, 2016–2019 · strength 0.15
  19. Raffaele Pezzilli · 3 shared papers, 2016–2019 · strength 0.15
  20. Ada Aita · 1 shared paper, 2021 · strength 0.15
  21. Diego Cecchin · 1 shared paper, 2021 · strength 0.13
  22. Laura Evangelista · 1 shared paper, 2021 · strength 0.13
  23. Francesca Bergamo · 1 shared paper, 2021 · strength 0.13
  24. Mario Gruppo · 2 shared papers, 2015–2017 · strength 0.13
  25. Davide Pastorelli · 2 shared papers, 2015–2018 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.